Ozempic and Eating Disorders: The Debate

If you are struggling: In the United States, the National Eating Disorders Association and ANAD both operate helplines and provider directories. For a mental health crisis, the 988 Suicide & Crisis Lifeline can be reached by call or text. Nothing in this article is medical advice.

---

GLP-1 drugs work in large part by turning down appetite. For someone with obesity and a long history of failed dieting, that is the point. For someone with an eating disorder, or a history of one, or a vulnerability nobody has spotted yet, it is also a description of the problem.

That is the whole debate, and it has not been settled - partly because the research that would settle it mostly does not exist.

What do we actually know?

Less than you would hope.

The National Eating Disorders Association states it plainly: “There has been very little research done on the impact of taking GLP-1’s in people with eating disorders. So the short answer to the question is… we don’t know yet” [1].

There is a structural reason for the gap. People with active eating disorders are typically excluded from clinical trials of weight-loss drugs. So the trials that established how well these medications work were not designed to tell us how they affect this group, and the group most at risk is the one we have the least data on.

What exists instead is mechanism-based reasoning, clinical experience, and a growing set of observational and experimental studies about attitudes, body image and stigma.

What are clinicians actually worried about?

NEDA lists the concerns directly [1]:

• Potential worsening of the cognitive and behavioral symptoms of eating disorders - body image concerns, weight obsession, drive for thinness, skipping meals, over-exercising
• The absence of studies on people with a history of, current, or risk for an eating disorder

ANAD adds a point that gets lost in most coverage: the experts disagree with each other [2].

“Even within the ED professional community, opinions differ. Some view GLP-1 medications as a valuable addition to a comprehensive treatment plan, while others worry they could trigger a latent eating disorder, cause relapse, be misused as appetite suppressants, reinforce weight stigma, or act as a ‘quick fix’ to a complex issue.”

ANAD also flags a diagnostic problem. Clinicians who specialize in weight management often have limited training in eating disorders, and eating disorder clinicians often have limited familiarity with GLP-1s, diabetes or cardiovascular disease. Someone with atypical anorexia nervosa - the diagnosis used for people in larger bodies with restrictive behavior - or non-purging bulimia can be misdiagnosed as having binge eating disorder, which changes the whole treatment plan [2].

A 2025 review in the peer-reviewed literature makes the same point about detection: restrictive eating often goes unnoticed in primary care, including in GLP-1 prescribing settings, because eating disorders in people at a higher or “normal” BMI are frequently judged by body weight rather than by behavior [3].

Is anyone actually screening?

Clinician education says yes, screen. The guidance is consistent and specific [4]:

1. Always screen for eating disorders before prescribing a GLP-1
2. Do not use them in active restrictive eating disorders such as anorexia nervosa or ARFID
3. Use caution in bulimia or binge-eating disorder, and only with a strong medical indication
4. Take patients’ concerns seriously

Whether that consistently happens in practice is a different question, and the access data suggests reasons for doubt. KFF’s late-2025 poll found that while 76% of US GLP-1 users got their drug from a primary care provider or specialist, 17% got it from an online provider or website and 9% from a medical spa or aesthetic medical center [5]. A fifteen-minute telehealth intake and a med spa consultation are not settings built for detecting an eating disorder.

This is not an argument against telehealth. It is an argument that the screening question is a fair one to ask any prescriber, whatever the setting.

What does the research on attitudes and body image show?

Here the evidence is thinner than clinical data but more than anecdote.

A study of US undergraduates (n = 225) found that greater interest in GLP-1 receptor agonists was associated with higher body shame, higher body surveillance, more weight concerns, more anti-fat bias and more disordered eating behaviors, along with lower body appreciation [6]. The study is cross-sectional and non-clinical, so it cannot establish direction of causation. But it suggests the people most drawn to these drugs may overlap with those most vulnerable on body image.

A second finding runs against a common assumption. Patients with anorexia nervosa and related disorders continue to overestimate their body size even after substantial weight change, and that perceptual distortion predicts poorer outcomes [3]. Weight loss does not fix body image. The expectation that it will is itself a risk.

What is the stigma nobody expected?

Here is the twist that has emerged most clearly in 2026: people who lose weight with a GLP-1 face more social judgment than people who lose the same weight by dieting.

A Georgetown study published April 9, 2026 in the American Psychological Association journal Stigma & Health tested this directly. Researchers recruited 402 US women ages 30 to 49, identifying as Black or white, who reported being overweight or having obesity. Each read a short vignette about a woman named Evette who had lost 15% of her body weight either through diet and exercise or with a GLP-1 medication [7]. When the weight loss came from a GLP-1, participants showed higher fat phobia, greater dislike, more blame and more desire for social distance.

The mechanism was specific. Social psychologist Stacy Post, a postdoctoral researcher at Georgetown Lombardi who led the research, said the perception of GLP-1-assisted weight loss as “an easy way out” predicted all of those outcomes [7].

“Our results show that the ‘easy way out’ perception does more than spark casual criticism. It can translate into measurable stigma, including fat phobia and a desire for social distance.”

The study turned up a second finding the researchers called unexpected: stigma was higher when Evette was portrayed as a white woman than as a Black woman, and the race of the participants themselves did not significantly change the outcome when the weight loss came from a GLP-1 [7]. The authors read that as evidence that “shortcut” assumptions may operate similarly across groups.

Another study found something stranger still: a lean woman who lost weight with a GLP-1 drew the same level of negative evaluation as a woman with obesity using the same method [8]. The judgment attaches to the method, not only the body.

An August 2026 commentary in the International Journal of Obesity named this as a distinct phenomenon - treatment-related stigma - arguing that GLP-1 judgments extend “beyond body size to include the perceived legitimacy and moral worthiness of pharmacologic weight management” [9].

The practical result is concealment. Medscape reported in July 2026 that more than 50% of US adults report having experienced weight stigma, which is linked to higher risk for disordered eating, diabetes, depression and social isolation [10]. Add treatment stigma on top and you get a large population managing a chronic medication in secret - which is exactly the condition under which problems go unnoticed.

Is body positivity actually over?

The numbers from fashion are not ambiguous.

Vogue Business analyzed every runway show and presentation on the official New York, London, Milan and Paris schedules for spring/summer 2025 and found 0.8% of 8,763 looks were plus-size (US 14+), with 94.9% straight-size (US 0 to 4). It warned that “progress has stalled and we are facing a worrying return to using extremely thin models, amid the Ozempic boom” [11].

By 2026 it had gotten narrower. Vogue Business’s fall/winter 2026 report counted 7,817 looks across 182 shows and found 0.3% plus-size, 2.1% mid-size and 97.6% straight-size - the lowest plus-size share since Vogue Business began tracking size inclusivity three years earlier. It named “growing use of GLP-1s” alongside rising conservatism and “obsessive self-optimization” as the backdrop [12]. Paris was the least inclusive of the four cities, at 99.5% straight-size.

British Vogue’s editorial director Chioma Nnadi told BBC Radio 4 the industry “should be concerned,” adding: “I do think maybe perhaps Ozempic has something to do with it.”

Lizzo, who has herself used a GLP-1, wrote in November 2025 that extended clothing sizes are disappearing and plus-size models are “no longer getting booked,” concluding that “we have a lot of work to do, to undo the effects of the ozempic boom” [13].

Clinicians see the same swing from the other side. Sam DeCaro, director of clinical outreach and education at The Renfrew Center, which specializes in eating disorder treatment, told USA TODAY in April 2026 there is concern about a “larger cultural swing towards the thin ideal yet again” [14].

Emily Hemendinger, an assistant professor of psychology at the University of Colorado Anschutz, has pointed out that body size trends run in cycles - flappers in the 1920s, Twiggy in the 1960s, “heroin chic” in the 1990s - and that what is different now is the availability of a medication that makes the current ideal reachable [15].

Northeastern University reporting in August 2026 put the stakes in context, citing NEDA’s estimate that roughly 9% of the US population will experience an eating disorder in their lifetime [16].

What is the case for the other side?

An honest version of this debate has to include the counter-argument, because it is strong.

Obesity is a disease with real consequences, and undertreating it is also harmful. The framing Oprah Winfrey brought to a mass audience - that she had “a predisposition that no amount of willpower is going to control” - is consistent with how obesity medicine has understood the condition for years. Withholding an effective treatment because of cultural discomfort has costs too.

Weight stigma predates these drugs by a century. The Guardian reported in August 2026 that experts describe body acceptance as having taken “a hard right turn” with the explosion of GLP-1s - but also that the media had cycled through idealization of weight loss repeatedly before [17]. The drugs accelerated something already moving.

Some clinicians see a legitimate role in binge eating disorder. ANAD notes that some eating disorder professionals view GLP-1s as a valuable part of a comprehensive plan [2]. Billie Jean King described exactly this hope publicly, telling Julia Louis-Dreyfus on the Wiser Than Me podcast that she is a binge eater and wanted to know whether the medication would “quiet the voices” [18].

Quieting food noise is not the same as restricting. For many people, constant intrusive thought about food is itself the distressing symptom. Relief from it is not obviously a step toward disordered eating.

None of these points dissolve the concerns. They just mean this is a genuine clinical disagreement, not a case of one side being obviously right.

What clinicians say to watch for

Not diagnostic criteria, and not a substitute for an evaluation - but the patterns that show up repeatedly in professional guidance as reasons to talk to a provider:

• Rigid calorie counting or food rules that get stricter over time
• Skipping meals because you “don’t feel hungry anyway,” rather than eating to a plan
• Weighing yourself more often, or distress when the number moves the wrong way
• Exercising to compensate for eating rather than for health
• Fear of stopping the medication because of what your eating might do
• Feeling worse about your body after losing weight, not better
• Hiding the medication from people close to you because of shame

NEDA’s summary is worth quoting in full, because it is more precise than most of the public argument [1]:

“While GLP-1 medications have been found to be helpful in the treatment of Type 2 diabetes and reduction of cardiovascular mortality, for individuals with eating disorders or disordered eating behaviors, these drugs can be harmful when not used for their intended purpose, when inadequately monitored or monitored by clinicians without eating disorder expertise, or when used for weight loss motivated by weight stigma or fat phobia.”

Read that carefully. It is not “these drugs cause eating disorders.” It is a list of the conditions under which harm is likely: wrong purpose, wrong monitoring, wrong motivation.

How to talk about other people’s bodies

One last thing, because it affects readers more than any clinical guideline.

Public speculation about which celebrity is “on it” is now routine, and it intensified around the 2026 Oscars red carpet, where multiple outlets named actors who had disclosed nothing. Teen Vogue’s August 2026 essay on how to talk about bodies in the GLP-1 era made the simplest available argument: the questions people ask aloud about strangers are the questions someone in recovery hears about themselves [19].

The practical version is short. Comment on what people do, not what they weigh. Do not treat weight loss as automatically good news or weight gain as automatically bad news. If somebody discloses a medication, that is information they chose to share, not an invitation to evaluate.

Where does this stand?

The debate is unresolved and will stay unresolved until there is research on the population that has been excluded from the research.

What is documented: the drugs suppress appetite; the professional bodies that treat eating disorders have raised specific, reasoned concerns; clinicians disagree among themselves; screening is recommended and inconsistently delivered; people who use these drugs face measurable extra stigma; and the cultural environment has swung hard back toward thinness by every measure fashion produces.

What is not documented: whether GLP-1s cause, trigger or worsen eating disorders at a population level, and in whom.

If you are considering one of these medications and you have any history of disordered eating - including the kind that never got a diagnosis - that history is worth raising with a prescriber before you start, not after. And if you are already taking one and things feel like they are getting worse rather than better, that is a reason to call someone, not to wait.

Sources

1. National Eating Disorders Association, “GLP-1 Medications and Eating Disorders” — https://www.nationaleatingdisorders.org/glp-and-eating-disorders
2. ANAD, “GLP-1 Medications & Eating Disorders” — https://anad.org/learning-library-old/glp-1-medications-eating-disorders
3. “Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes,” PubMed Central — https://pmc.ncbi.nlm.nih.gov/articles/PMC12694361
4. The Curbsiders, “#504: Adult Eating Disorders in the GLP-1 Era” — https://thecurbsiders.com/curbsiders-podcast/504-adult-eating-disorders-in-the-glp-1-era
5. KFF, “KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use” (November 14, 2025) — https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/
6. Markey et al., “Body image and interest in GLP-1 weight loss medications,” Body Image (2025) — https://www.sciencedirect.com/science/article/pii/S1740144525000415
7. Georgetown Lombardi Comprehensive Cancer Center, “New study examines stigma toward women who lose weight using GLP-1 medications” (April 10, 2026) — https://lombardi.georgetown.edu/news-release/new-study-examines-stigma-toward-women-who-lose-weight-using-glp-1-medications
8. “The Effect of GLP-1 Receptor Agonist Use on Negative Evaluations of Women with Higher and Lower Body Weight,” PubMed Central — https://pmc.ncbi.nlm.nih.gov/articles/PMC12439114/
9. International Journal of Obesity, “GLP-1 receptor agonists and the emergence of treatment-related stigma: a call for conceptual clarity” (August 17, 2026) — https://www.nature.com/articles/s41366-026-02200-5
10. Medscape, “Weight Stigma Is Growing Across Social Networks” (July 15, 2026) — https://www.medscape.com/viewarticle/weight-stigma-growing-across-social-networks-do-glp-1-2026a1000nrn
11. NBC News, “Is the era of body positivity over? Some experts worry about return of ‘thinness’ as the norm” — https://www.nbcnews.com/pop-culture/viral/era-body-positivity-experts-worry-return-thinness-norm-rcna184050
12. Vogue Business, “The Vogue Business Fall/Winter 2026 size inclusivity report” — https://www.vogue.com/article/the-vogue-business-fall-winter-2026-size-inclusivity-report
13. ELLE Canada, “Skinny Culture Is Back With a Vengeance” (July 20, 2026) — https://www.ellecanada.com/beauty/health-and-fitness/skinny-culture-is-back-with-a-vengeance-so-whatever-happened-to-body-positivity
14. TODAY, “Lizzo Responds to Weight Loss Backlash” (November 24, 2025) — https://www.today.com/health/mind-body/lizzo-essay-backlash-weight-loss-body-positive-rcna245605
15. USA TODAY, “Diet pills, the ’90s and why the GLP-1 craze is worrying some experts” (April 30, 2026) — https://www.usatoday.com/story/life/health-wellness/2026/04/30/90s-diet-pills-glp1s-body-image/89821900007/
16. University of Colorado Anschutz, “Why ‘Skinny’ Culture Is Back” (January 30, 2026) — https://news.cuanschutz.edu/news-stories/why-skinny-culture-is-back-and-what-it-means-for-body-image-and-mental-health
17. Northeastern Global News, “Diet culture is back. Are GLP-1s fueling eating disorders?” (August 19, 2026) — https://news.northeastern.edu/2026/08/19/ozempic-eating-disorder-diet-culture/
18. The Guardian, “People’s bodies are changing in the age of Ozempic. How are we meant to talk about it?” (August 25, 2026) — https://www.theguardian.com/wellness/2026/aug/25/ozempic-glp-1-experts-body-conversations
19. TODAY, “32 Celebrities Who’ve Opened Up About Taking Ozempic or Weight-Loss Drugs” — https://www.today.com/health/celebrities-on-ozempic-rcna129740
20. Teen Vogue, “How to Talk About Ariana Grande in the Ozempic Era” (August 4, 2026) — https://www.teenvogue.com/story/how-to-talk-about-ariana-grande-in-the-ozempic-era-op-ed
21. “Social Perceptions of GLP-1-assisted Weight Loss in Black and White Women with Obesity,” Stigma & Health via PubMed Central (2026) — https://pmc.ncbi.nlm.nih.gov/articles/PMC13196875